Ypsomed
Ypsomed Holding AG, commonly known as Ypsomed, is a leading Swiss company headquartered in Burgdorf, Switzerland (CH). Founded in 1984, Ypsomed has established itself as a key player in the medical technology industry, specialising in the development and manufacturing of innovative drug delivery systems and diabetes management solutions. With a strong presence in Europe and expanding operations in Asia and North America, Ypsomed is renowned for its cutting-edge products, including insulin delivery devices and pen systems. The company’s commitment to quality and user-centric design sets it apart in a competitive market. Ypsomed has achieved significant milestones, including partnerships with major pharmaceutical companies, solidifying its position as a trusted provider in the healthcare sector.
DitchCarbon Score
How does Ypsomed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ypsomed's score of 66 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ypsomed's reported carbon emissions
In 2023, Ypsomed AG reported total greenhouse gas emissions of approximately 2,404,000 kg CO2e for Scope 1, with no reported emissions for Scope 2. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2040, using 2020 as the base year. Ypsomed has established near-term targets to reduce absolute Scope 1 and 2 emissions by 32% by 2027 and to cut Scope 3 emissions by 52% per million CHF of value added by 2030. For the long term, the company aims to achieve a 90% reduction in absolute Scope 1 and 2 emissions by 2030 and a 97% reduction in Scope 3 emissions per million CHF of value added by 2040. The company’s commitment aligns with the Science Based Targets initiative (SBTi) and reflects its dedication to addressing climate change within the healthcare technology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000 | - | 0,000 | - |
| Scope 3 | - | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ypsomed is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
